B7-H3 Inhibitors in Oncology Clinical Trials: A Review

B7-H3 Inhibitors in Oncology Clinical Trials: A Review

B7-H3 is a transmembrane receptor highly prevalent on malignant cells and plays an important role in adaptive immunity that is not fully elucidated. Targeted B7-H3 inhibitors, including antibody-drug conjugates, radioimmunotherapy, and monoclonal antibodies, are a new class of antineoplastic agents...

Full description

Bibliographic Details
Main Authors: Kavanya Feustel, Jared Martin, Gerald S. Falchook
Format: Article
Language:English
Published: Innovative Healthcare Institute 2024-02-01
Series:Journal of Immunotherapy and Precision Oncology
Subjects:
b7-h3
cd276
cancer
clinical trial
review
Online Access:https://jipo.org/doi/pdf/10.36401/JIPO-23-18

Similar Items

Similar Items